UPDATE – Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

February 6, 2024

https://www.globenewswire.com/news-release/2024/02/06/2824482/0/en/UPDATE-Gain-Therapeutics-GT-02287-Completely-Restores-Motor-Function-in-Mouse-Models-of-Parkinson-s-Disease.html

BETHESDA, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc., (Nasdaq:GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces preclinical data demonstrating that its clinical-stage GCase regulator GT-02287 provided neuroprotection and restored motor function in Parkinson’s disease models following delayed administration. The data was accepted as a late-breaker abstract and will be presented at the 20th Annual WORLDSymposium™ being held in San Diego this week.

Read more at globenewswire.com

Related news for (GANX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.